DK1808168T3 - Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau - Google Patents

Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau

Info

Publication number: DK1808168T3
Authority: DK; Denmark
Prior art keywords: treatment; conditions; relieved; diabetes; raising
Prior art date: 2005-01-10

Application number

DK07004743T

Other languages

English (en)

Inventor

James N Leonard

Hussien A Al-Shamma

Robert M Jones

Zhi-Liang Chu

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2009-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36570727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1808168(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-09 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2009-10-05 Application granted granted Critical

2009-10-05 Publication of DK1808168T3 publication Critical patent/DK1808168T3/da

Links

102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
239000008280 blood Substances 0.000 title 1
210000004369 blood Anatomy 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Neurology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Pathology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Cardiology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Psychology (AREA)

DK07004743T 2005-01-10 2006-01-09 Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau DK1808168T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US64308605P	2005-01-10	2005-01-10
US68317205P	2005-05-19	2005-05-19
US72688005P	2005-10-14	2005-10-14
PCT/US2006/000510 WO2006076231A2 (en)	2005-01-10	2006-01-09	Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level

Publications (1)

Publication Number	Publication Date
DK1808168T3 true DK1808168T3 (da)	2009-10-05

Family

ID=36570727

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK06717678.4T DK1758565T4 (da)	2005-01-10	2006-01-09	Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer.
DK07004743T DK1808168T3 (da)	2005-01-10	2006-01-09	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK06717678.4T DK1758565T4 (da)	2005-01-10	2006-01-09	Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer.

Country Status (35)

Country	Link
US (12)	US20060154866A1 (da)
EP (9)	EP1997484A3 (da)
JP (8)	JP4118323B1 (da)
KR (5)	KR20100129328A (da)
CN (2)	CN102218141A (da)
AR (1)	AR052082A1 (da)
AT (2)	ATE432693T1 (da)
AU (3)	AU2006205164B2 (da)
BR (1)	BRPI0606727A (da)
CA (2)	CA2593427C (da)
CL (1)	CL2010000565A1 (da)
CR (1)	CR9220A (da)
CY (2)	CY1109260T1 (da)
DE (2)	DE602006006765D1 (da)
DK (2)	DK1758565T4 (da)
DO (2)	DOP2006000008A (da)
EA (1)	EA011883B1 (da)
ES (2)	ES2327268T5 (da)
GT (1)	GT200600004A (da)
HN (1)	HN2006000971A (da)
HR (2)	HRP20090403T4 (da)
IL (1)	IL184364A0 (da)
MX (1)	MX2007008376A (da)
NI (1)	NI200700174A (da)
NO (2)	NO331089B1 (da)
NZ (4)	NZ587368A (da)
PA (1)	PA8659301A1 (da)
PE (2)	PE20061116A1 (da)
PL (2)	PL1758565T5 (da)
PT (2)	PT1758565E (da)
RS (2)	RS51127B (da)
SG (2)	SG189762A1 (da)
SI (2)	SI1758565T1 (da)
TW (1)	TW200637534A (da)
WO (1)	WO2006076231A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRPK20110926B3 (hr) *	2001-02-24	2013-05-31	Boehringer Ingelheim Pharma Gmbh & Co.Kg.	Derivati ksantina, njihova proizvodnja i upotreba kao lijekova
EP1411968B1 (en) *	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PT1599468E (pt)	2003-01-14	2008-01-14	Arena Pharm Inc	Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko)	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2591922A1 (en) *	2004-12-24	2006-06-29	Prosidion Limited	G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007027225A2 (en)	2005-04-27	2007-03-08	Arena Pharmaceuticals, Inc.	Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
MX2007016508A (es) *	2005-06-30	2008-03-04	Prosidion Ltd	Agonistas del receptor acoplado a la proteina g.
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007056580A2 (en) *	2005-11-08	2007-05-18	Pharmadyn, Inc.	Methods and compositions for treating diseases associated with pathogenic proteins
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PT1971862E (pt)	2006-04-11	2011-02-14	Arena Pharm Inc	Métodos de utilização do receptor gpr119 para identificar compostos úteis para aumentar a massa óssea num indivíduo
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CA2873524C (en)	2006-05-04	2018-02-20	Boehringer Ingelheim International Gmbh	A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008008895A1 (en) *	2006-07-13	2008-01-17	Smithkline Beecham Corporation	Gpr119 agonists for the treatment of diabetes and related disorders
AU2007291254A1 (en) *	2006-08-30	2008-03-06	Inovacia Ab	Pyrimidine compounds for treating GPR119 related disorders
WO2008076243A2 (en) *	2006-12-14	2008-06-26	Merck & Co., Inc.	Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CL2008000018A1 (es) *	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
HRP20110852T1 (hr) *	2007-01-04	2011-12-31	Prosidion Limited	PIPERIDINSKI AGONISTI GPCR-a
PE20081849A1 (es) *	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
WO2008141074A1 (en) *	2007-05-10	2008-11-20	Salk Institute For Biological Studies	Identification of compounds that protect against amyloid diseases
CA2693169C (en)	2007-07-19	2016-01-12	Metabolex, Inc.	N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
PE20090938A1 (es) *	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ583495A (en)	2007-09-20	2011-11-25	Irm Llc	Compounds and compositions as modulators of gpr119 activity
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
EP2280704B1 (en) *	2008-03-31	2015-05-13	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds and uses thereof
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) *	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009143049A1 (en) *	2008-05-19	2009-11-26	Schering Corporation	Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
ATE557024T1 (de) *	2008-07-10	2012-05-15	Prosidion Ltd	Piperidinverbindungen als gpcr-agonisten
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CN102149407A (zh) *	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko)	2008-10-17	2011-08-05	동아제약주식회사	디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CN101723947B (zh) *	2008-10-21	2012-05-30	山东轩竹医药科技有限公司	二肽酶-ⅳ抑制剂化合物
MX2011006713A (es)	2008-12-23	2011-07-13	Boehringer Ingelheim Int	Formas salinas de compuesto organico.
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US20220387305A1 (en) *	2009-01-12	2022-12-08	Biokier, Inc.	Composition and method for treatment of diabetes
KR101694136B1 (ko)	2009-02-13	2017-01-09	베링거 인겔하임 인터내셔날 게엠베하	Ｓｇｌｔ２ 억제제, ｄｐｐ－ｉｖ 억제제 및 임의로 추가의 당뇨병 치료제를 포함하는 약제학적 조성물 및 이의 용도
EP2414348B1 (en)	2009-04-03	2013-11-20	Merck Sharp & Dohme Corp.	Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
GEP20135907B (en) *	2009-06-05	2013-08-12	Pfizer	L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
CN102803214A (zh)	2009-06-24	2012-11-28	贝林格尔.英格海姆国际有限公司	新化合物、与之相关的药物组合物和方法
TW201113269A (en)	2009-06-24	2011-04-16	Boehringer Ingelheim Int	New compounds, pharmaceutical composition and methods relating thereto
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SMT201700583T1 (it) *	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
JP5909185B2 (ja)	2009-10-01	2016-04-26	シマベイセラピューティクス，インコーポレーテッド	置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
JP2013510834A (ja)	2009-11-16	2013-03-28	メリテク	［１，５］‐ジアゾシン誘導体
MX364651B (es)	2009-11-27	2019-05-03	Boehringer Ingelheim Int Gmbh Star	Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
EP2528894A1 (en)	2010-01-27	2012-12-05	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011094632A1 (en) *	2010-01-29	2011-08-04	The Uab Research Foundation	Method for administration of insulin and pharmaceutical composition thereof
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US20130023494A1 (en)	2010-04-06	2013-01-24	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112012028136A2 (pt)	2010-05-05	2016-08-09	Boehringer Ingelheim Int	terapia de combinaçao
JP5847813B2 (ja)	2010-06-23	2016-01-27	シマベイセラピューティクス，インコーポレーテッド	５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
MX2012014247A (es)	2010-06-24	2013-01-18	Boehringer Ingelheim Int	Terapia para la diabetes.
PH12013500547A1 (en)	2010-09-22	2013-06-10	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2012135570A1 (en)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8962636B2 (en)	2011-07-15	2015-02-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2015522080A (ja)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
CN103344773B (zh) *	2013-06-19	2015-04-15	天津美德太平洋科技有限公司	一种胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
CN105637363B (zh)	2013-08-01	2017-06-27	庆熙大学校产学协力团	预防或治疗糖尿病的药物组合物，预防或治疗糖尿病的方法，以及筛选糖尿病治疗药物的方法
WO2015016682A1 (ko)	2013-08-01	2015-02-05	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
KR20230151072A (ko)	2015-01-06	2023-10-31	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 상태의 치료 방법
KR20220070057A (ko)	2015-03-09	2022-05-27	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
CN108349891B (zh)	2015-06-22	2022-04-05	艾尼纳制药公司	用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
CA3022202A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
EP3493807A1 (en)	2016-08-03	2019-06-12	CymaBay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
CA3058806A1 (en)	2017-04-03	2018-10-11	Coherus Biosciences Inc.	Ppar.gamma. agonist for treatment of progressive supranuclear palsy
WO2018236896A1 (en)	2017-06-19	2018-12-27	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of nafld and nash
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
RU2768943C1 (ru)	2018-09-12	2022-03-25	Тон-А Ст Ко., Лтд.	Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой инфильтрации печени, содержащая лиганд gpr119 в качестве активного ингредиента
US20220265652A1 (en)	2019-07-08	2022-08-25	Mankind Pharma Ltd.	Combination therapy of gpr119 agonists and dpp-4 inhibitors
WO2021182877A1 (ko) *	2020-03-11	2021-09-16	동아에스티 주식회사	당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물
CN116348464A (zh) *	2020-10-12	2023-06-27	杭州中美华东制药有限公司	苯并咪唑酮类glp-1受体激动剂及其用途
KR20250093570A (ko) *	2022-11-10	2025-06-24	에이스랜드 테라퓨틱스 (홍콩) 리미티드	Sos1 억제제

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US751426A (en) *		1904-02-02		Safety hair-pin
US747699A (en) *	1903-09-05	1903-12-22	Achilles C Gough	Universal sanding-machine.
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4704362A (en) *	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4265874A (en) *	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DD296075A5 (de)	1989-08-07	1991-11-21	Martin-Luther-Universitaet Halle-Wittenberg,De	Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
ES2099158T3 (es)	1990-04-14	1997-05-16	New England Medical Center Inc	Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
US5462856A (en)	1990-07-19	1995-10-31	Bunsen Rush Laboratories, Inc.	Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
JPH07504158A (ja)	1991-10-22	1995-05-11	ニュー　イングランド　メディカル　センター　ホスピタルズ　インク	ジペプチジル−アミノペプチダーゼｉｖ型のインヒビタ
MX9206628A (es)	1991-11-22	1993-05-01	Boehringer Ingelheim Pharma	Ester de prolinaboronato y metodo para su preparacion.
US6100042A (en) *	1993-03-31	2000-08-08	Cadus Pharmaceutical Corporation	Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
DE19616486C5 (de)	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
AU4721897A (en)	1996-10-25	1998-05-22	Tanabe Seiyaku Co., Ltd.	Tetrahydroisoquinoline derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6040145A (en)	1997-05-07	2000-03-21	Tufts University	Potentiation of the immune response
US6100234A (en)	1997-05-07	2000-08-08	Tufts University	Treatment of HIV
US6183974B1 (en) *	1997-07-31	2001-02-06	The General Hospital Corporation	Screening assays for G protein coupled receptor agonists and antagonists
ES2285785T3 (es)	1997-09-29	2007-11-16	Point Therapeutics, Inc.	Estimulacion de celulas hematopoyeticas in vitro.
JP4095772B2 (ja)	1997-11-18	2008-06-04	財団法人微生物化学研究会	新規生理活性物質スルフォスチン、その製造法及びその用途
WO1999038501A2 (en)	1998-02-02	1999-08-05	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
US5922576A (en) *	1998-02-27	1999-07-13	The John Hopkins University	Simplified system for generating recombinant adenoviruses
NZ507730A (en)	1998-05-04	2004-02-27	Point Therapeutics Inc	Hematopoietic stimulation
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US6355614B1 (en)	1998-06-05	2002-03-12	Point Therapeutics	Cyclic boroproline compounds
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
EP1104293A1 (en)	1998-08-21	2001-06-06	Point Therapeutics, Inc.	Regulation of substrate activity
AU6294899A (en) *	1998-10-07	2000-04-26	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6242422B1 (en)	1998-10-22	2001-06-05	Idun Pharmacueticals, Inc.	(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
NZ527622A (en) *	1998-11-20	2005-03-24	Arena Pharm Inc	Human orphan G-protein-coupled receptors
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2000191616A (ja)	1998-12-24	2000-07-11	Senju Pharmaceut Co Ltd	新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
US20030125539A1 (en) *	1999-02-22	2003-07-03	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
US6221660B1 (en) *	1999-02-22	2001-04-24	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
GB9906714D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for improving fertility
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
JP4121215B2 (ja)	1999-05-17	2008-07-23	財団法人微生物化学研究会	スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
JP2003500360A (ja)	1999-05-25	2003-01-07	ポイントセラピューティクス，インコーポレイテッド	ボロプロリン化合物類を含む抗癌剤
US6617340B1 (en)	1999-07-29	2003-09-09	Novartis Ag	N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6653064B1 (en) *	1999-09-23	2003-11-25	Boehringer Ingelheim International Gmbh	Method for identifying compounds useful in the therapy of bone disorders
GB9923177D0 (en)	1999-09-30	1999-12-01	Pfizer Ltd	Novel polypeptide
EP1228061A4 (en)	1999-11-12	2004-12-15	Guilford Pharm Inc	DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS
US6380398B2 (en)	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DK1248604T4 (da)	2000-01-21	2012-05-21	Novartis Ag	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
WO2001055105A1 (en)	2000-01-24	2001-08-02	Novo Nordisk A/S	N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) *	2000-03-15	2003-08-19	Novartis Ag	Methods and compositions for treatment of diabetes and related conditions via gene therapy
GB0010188D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
DK1287133T3 (da) *	2000-05-18	2007-03-26	Bayer Healthcare Ag	Regulering af human dopamin-lignende G-protein-koblet receptor
TW583185B (en)	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6432969B1 (en)	2000-06-13	2002-08-13	Novartis Ag	N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2001096597A2 (en) *	2000-06-13	2001-12-20	Glaxo Group Limited	High throughput screening of compounds for biological activity
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
PL360856A1 (en)	2000-07-04	2004-09-20	Novo Nordisk A/S	Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
DE60128475T2 (de) *	2000-07-25	2008-02-07	Merck & Co., Inc.	N-substituierte indole mit anwendung in der behandlung von diabetes
EP1930319B1 (en) *	2000-08-10	2012-05-02	Mitsubishi Tanabe Pharma Corporation	Proline derivatives and use thereof as drugs
JP2004035574A (ja)	2000-10-06	2004-02-05	Tanabe Seiyaku Co Ltd	脂肪族含窒素五員環化合物
JP4329290B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	脂肪族含窒素五員環化合物
DE60135862D1 (de)	2000-10-06	2008-10-30	Mitsubishi Tanabe Pharma Corp	Aliphatische stickstoffhaltige fünfgliedrige ringverbindungen
JP4329291B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	含窒素五員環化合物
AUPR107800A0 (en)	2000-10-27	2000-11-23	University Of Sydney, The	Peptide and nucleic acid molecule ii
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
AU2002219890B2 (en)	2000-11-27	2007-06-14	Arena Pharmaceuticals, Inc.	Endogenous and non-endogenous versions of human G protein-coupled receptors
US20030180813A1 (en) *	2000-12-01	2003-09-25	Takahide Ohishi	Method of screening remedy for diabetes
WO2002051836A1 (en)	2000-12-27	2002-07-04	Kyowa Hakko Kogyo Co., Ltd.	Dipeptidyl peptidase iv inhibitor
WO2002055088A1 (en)	2001-01-16	2002-07-18	Nippon Kayaku Kabushiki Kaisha	Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
US6397767B1 (en) *	2001-02-01	2002-06-04	Case Corporation	Knife applicator for applying liquid fertilizer in the ground
JP4213390B2 (ja)	2001-02-02	2009-01-21	武田薬品工業株式会社	縮合複素環化合物
ATE366724T1 (de)	2001-02-02	2007-08-15	Takeda Pharmaceutical	Kondensierte heterocyclische derivate
HRPK20110926B3 (hr) *	2001-02-24	2013-05-31	Boehringer Ingelheim Pharma Gmbh & Co.Kg.	Derivati ksantina, njihova proizvodnja i upotreba kao lijekova
JP2002265439A (ja)	2001-03-08	2002-09-18	Mitsubishi Pharma Corp	シアノピロリジン誘導体およびその医薬用途
AU2002338329B2 (en) *	2001-03-27	2006-09-07	The Regents Of The University Of California	Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
DE60226723D1 (de)	2001-03-27	2008-07-03	Merck & Co Inc	Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
FR2822826B1 (fr)	2001-03-28	2003-05-09	Servier Lab	Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en)	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr)	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7098239B2 (en)	2001-06-20	2006-08-29	Merck & Co., Inc	Dipeptidyl peptidase inhibitors for the treatment of diabetes
US7253172B2 (en)	2001-06-20	2007-08-07	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
WO2003002593A2 (en)	2001-06-27	2003-01-09	Probiodrug Ag	Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
WO2003002595A2 (en)	2001-06-27	2003-01-09	Probiodrug Ag	Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2003002531A2 (en)	2001-06-27	2003-01-09	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60221983T2 (de)	2001-06-27	2008-05-15	Smithkline Beecham Corp.	Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ES2296962T3 (es)	2001-06-27	2008-05-01	Smithkline Beecham Corporation	Pirrolidinas como inhibidores de dipeptidil peptidasa.
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
ATE388951T1 (de)	2001-07-03	2008-03-15	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10143840A1 (de)	2001-09-06	2003-03-27	Probiodrug Ag	Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
US20040259883A1 (en)	2001-09-14	2004-12-23	Hiroshi Sakashita	Thiazolidine derivative and medicinal use thereof
JPWO2003026661A1 (ja)	2001-09-14	2005-01-06	山之内製薬株式会社	インスリン分泌促進剤及び新規なピリミジン誘導体
WO2003024965A2 (en)	2001-09-19	2003-03-27	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
GEP20063908B (en) *	2001-10-18	2006-08-25	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) *	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125445D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Protease Inhibitors
GB0125446D0 (en) *	2001-10-23	2001-12-12	Ferring Bv	Novel anti-diabetic agents
US6861440B2 (en)	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
WO2003038123A2 (en)	2001-10-31	2003-05-08	Novartis Ag	Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
US20030125304A1 (en) *	2001-11-09	2003-07-03	Hans-Ulrich Demuth	Substituted amino ketone compounds
JP4771661B2 (ja)	2001-11-26	2011-09-14	トラスティーズオブタフツカレッジ	Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
WO2003045228A2 (en)	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
WO2003057144A2 (en)	2001-12-26	2003-07-17	Guilford Pharmaceuticals	Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en)	2001-12-27	2004-04-27	Hoffman-La Roche Inc.	Pyrido[2,1-A]Isoquinoline derivatives
WO2003072528A2 (en)	2002-02-08	2003-09-04	Idun Pharmaceuticals, Inc.	(substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
CN1308311C (zh)	2002-02-13	2007-04-04	霍夫曼-拉罗奇有限公司	新型吡啶－和喹啉－衍生物
EP1476435B1 (en)	2002-02-13	2010-06-30	F. Hoffmann-La Roche Ag	Novel pyridin- and pyrimidin-derivatives
US6906074B2 (en)	2002-02-22	2005-06-14	Nippon Zoki Pharmaceutical Co., Ltd.	2-phenylpiperazine derivatives
EP1338595B1 (en) *	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthine derivatives as DPP-IV inhibitors
JP2004043429A (ja)	2002-02-25	2004-02-12	Eisai Co Ltd	新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
NZ534877A (en)	2002-02-28	2006-05-26	Prosidion Ltd	Glutaminyl based DPIV inhibitors
HUP0200849A2 (hu) *	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
EP1489088B1 (en)	2002-03-25	2008-08-13	Nippon Kayaku Kabushiki Kaisha	Novel alpha-amino-n-(diaminophosphinyl)lactam derivative
DE60316416T2 (de)	2002-03-25	2008-06-26	Merck & Co., Inc.	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
JP4329382B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
JP4329381B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
CN1633420A (zh)	2002-04-08	2005-06-29	托伦脱药品有限公司	噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途
JP2003300977A (ja)	2002-04-10	2003-10-21	Sumitomo Pharmaceut Co Ltd	キサンチン誘導体
AU2003235913A1 (en)	2002-05-09	2003-11-11	Taisho Pharmaceutical Co., Ltd.	Cyanopyrrolidine derivatives
JP2004026820A (ja)	2002-05-09	2004-01-29	Taisho Pharmaceut Co Ltd	ジペプチジルペプチダーゼｉｖ阻害剤
JP2003327532A (ja)	2002-05-10	2003-11-19	Takeda Chem Ind Ltd	ペプチダーゼ阻害剤
GB0212412D0 (en)	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
PL210408B1 (pl)	2002-06-03	2012-01-31	Novartis Ag	Zastosowanie podstawionych cyjanopirolidyn do wytwarzania leku do modulowania hiperlipidemii
AU2003233010A1 (en)	2002-06-04	2003-12-19	Pfizer Products Inc.	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US6710040B1 (en)	2002-06-04	2004-03-23	Pfizer Inc.	Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
BR0311608A (pt)	2002-06-04	2005-02-22	Pfizer Prod Inc	Amidas cìclicas fluoradas como inibidores da dipeptidil-peptidase iv
US20060100199A1 (en) *	2002-06-06	2006-05-11	Seiji Yoshikawa	Novel condensed imidazole derivatives
HUP0202001A2 (hu)	2002-06-14	2005-08-29	Sanofi-Aventis	DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2004026678A (ja)	2002-06-24	2004-01-29	Microbial Chem Res Found	２型糖尿病治療剤
EP1578434A2 (en)	2002-07-09	2005-09-28	Point Therapeutics, Inc.	Methods and compositions relating to isoleucine boroproline compounds
JPWO2004007446A1 (ja)	2002-07-10	2005-11-10	アステラス製薬株式会社	新規なアゼチジン誘導体又はその塩
US7208498B2 (en) *	2002-07-15	2007-04-24	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200401635A (en)	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
JP4542757B2 (ja)	2002-08-08	2010-09-15	武田薬品工業株式会社	縮合複素環化合物
US7547710B2 (en)	2002-08-08	2009-06-16	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds as peptidase inhibitors
DE10236667B4 (de) *	2002-08-09	2007-06-06	J. Eberspächer GmbH & Co. KG	Abgasanlage für den Verbrennungsmotor eines Kraftfahrzeugs
WO2004034968A2 (en) *	2002-08-20	2004-04-29	The Regents Of The University Of California	Combination therapy for controlling appetites
CN100522962C (zh)	2002-08-21	2009-08-05	贝林格尔英格海姆法玛两合公司	8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备方法及作为药物制剂的用途
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (de)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
PL374664A1 (en)	2002-08-29	2005-10-31	Taisho Pharmaceutical Co, Ltd.	Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
EP1538217A4 (en) *	2002-09-11	2006-09-27	Astellas Pharma Inc	SCREENING METHOD FOR INSULATION STOP ENHANCER
US20060039974A1 (en) *	2002-09-11	2006-02-23	Takeda Pharmaceutical Company Limited	Sustained release preparation
DE60315687T2 (de)	2002-10-07	2008-06-05	Merck & Co., Inc.	Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
AU2003269850A1 (en)	2002-10-08	2004-05-04	Novo Nordisk A/S	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AR041470A1 (es) *	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
JP4352001B2 (ja)	2002-10-18	2009-10-28	メルクエンドカムパニーインコーポレーテッド	糖尿病の治療または予防のためのベータ−アミノ複素環式ジペプチジルペプチダーゼ阻害剤
EP1553937B1 (en)	2002-10-23	2010-06-02	Bristol-Myers Squibb Company	Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
AU2003286776A1 (en)	2002-10-30	2004-06-07	Guilford Pharmaceuticals Inc.	Novel inhibitors of dipeptidyl peptidase iv
AU2003280680A1 (en)	2002-11-01	2004-06-18	Sumitomo Pharmaceuticals Co., Ltd.	Xanthine compound
US7157490B2 (en)	2002-11-07	2007-01-02	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de)	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
MXPA05005260A (es)	2002-11-18	2005-07-25	Pfizer Prod Inc	Amidas ciclicas fluoradas que inhiben la dipeptidil peptidasa iv.
DE10256264A1 (de)	2002-12-03	2004-06-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UY28103A1 (es)	2002-12-03	2004-06-30	Boehringer Ingelheim Pharma	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
JP2006510630A (ja) *	2002-12-04	2006-03-30	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
US7420079B2 (en)	2002-12-09	2008-09-02	Bristol-Myers Squibb Company	Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
CA2505771A1 (en)	2002-12-10	2004-06-24	Novartis Ag	Combination of an dpp-iv inhibitor and a ppar-alpha compound
JP4504924B2 (ja) *	2002-12-20	2010-07-14	メルク・シャープ・エンド・ドーム・コーポレイション	糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
US6982164B2 (en) *	2003-01-10	2006-01-03	Mgp Ingredients, Inc.	Unhydrolyzed jojoba protein products having high simmondsin concentration
PT1599468E (pt) *	2003-01-14	2008-01-14	Arena Pharm Inc	Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
EP1589969A4 (en) *	2003-01-17	2008-08-13	Merck & Co Inc	3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
JP2004244412A (ja)	2003-01-20	2004-09-02	Kotobuki Seiyaku Kk	４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
AU2004210149A1 (en)	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PT1595866T (pt)	2003-01-31	2016-09-14	Sanwa Kagaku Kenkyusho Co	Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
WO2004071454A2 (en)	2003-02-13	2004-08-26	Guilford Pharmaceuticals Inc.	Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
US20070066590A1 (en) *	2003-02-24	2007-03-22	Jones Robert M	Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
AU2003207881A1 (en)	2003-02-28	2004-09-17	Aic	Dipeptidyl peptidase inhibitors
WO2004076434A1 (en)	2003-02-28	2004-09-10	Aic	Dipeptidyl peptidase inhibitors
JP2004269468A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269469A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
AR043515A1 (es)	2003-03-19	2005-08-03	Merck & Co Inc	Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en)	2003-03-24	2004-10-07	Merck & Co., Inc	Process to chiral beta-amino acid derivatives
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
WO2004087650A2 (en)	2003-03-27	2004-10-14	Merck & Co. Inc.	Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en)	2003-04-10	2004-10-28	Smithkline Beecham Corporation	Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
WO2004096806A1 (ja)	2003-04-30	2004-11-11	Sumitomo Pharmaceuticals Co. Ltd.	縮合イミダゾール誘導体
WO2004099134A2 (en)	2003-05-05	2004-11-18	Prosidion Ltd.	Glutaminyl based dp iv-inhibitors
WO2004098591A2 (en) *	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US7083933B1 (en) *	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
ATE447574T1 (de)	2003-05-14	2009-11-15	Merck & Co Inc	3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
EP1627870A1 (en)	2003-05-15	2006-02-22	Taisho Pharmaceutical Co., Ltd	Cyanofluoropyrrolidine derivative
EP1631679A2 (en)	2003-05-21	2006-03-08	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
WO2004104216A2 (en)	2003-05-21	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
AU2003902828A0 (en)	2003-06-05	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
US7332520B2 (en)	2003-06-06	2008-02-19	Merck & Co., Inc.	Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20070099884A1 (en)	2003-06-06	2007-05-03	Erondu Ngozi E	Combination therapy for the treatment of diabetes
AU2003902946A0 (en)	2003-06-12	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
CA2527806A1 (en)	2003-06-17	2004-12-29	Merck & Co., Inc.	Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10327439A1 (de)	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
ATE437876T1 (de)	2003-06-20	2009-08-15	Hoffmann La Roche	Hexahydropyridoisochinoline als dpp-iv- inhibitoren
RS52397B (sr)	2003-06-20	2013-02-28	F.Hoffmann-La Roche Ag	Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori
JO2625B1 (en) *	2003-06-24	2011-11-01	ميرك شارب اند دوم كوربوريشن	Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2005023038A (ja)	2003-07-04	2005-01-27	Taisho Pharmaceut Co Ltd	慢性腎疾患治療薬
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko) *	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
JP2006528187A (ja)	2003-07-21	2006-12-14	スミスクラインビーチャムコーポレーション	（２Ｓ，４Ｓ）−４−フルオロ−１−［４−フルオロ−β−（４−フルオロフェニル）−Ｌ−フェニルアラニル］−２−ピロリジンカルボニトリルｐ−トルエンスルホン酸塩及びその無水結晶形態
US7008957B2 (en) *	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
DE10333935A1 (de)	2003-07-25	2005-02-24	Aventis Pharma Deutschland Gmbh	Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7094800B2 (en) *	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
PE20050249A1 (es)	2003-07-25	2005-06-01	Aventis Pharma Gmbh	Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
AU2004261186A1 (en)	2003-07-31	2005-02-10	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en)	2003-08-20	2005-03-03	Pfizer Products Inc.	Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
EP1659123A1 (en)	2003-08-29	2006-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrazole derivative
HU227684B1 (en)	2003-08-29	2011-11-28	Sanofi Aventis	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1662876A4 (en)	2003-09-02	2009-01-14	Merck & Co Inc	NEW CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV HEMMER
WO2005023762A1 (en)	2003-09-04	2005-03-17	Abbott Laboratories	Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005030751A2 (en)	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200530157A (en)	2003-09-09	2005-09-16	Japan Tobacco Inc	Dipeptidyl peptidase iv inhibitor
WO2005030127A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005033099A2 (en)	2003-10-03	2005-04-14	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
EP1671649B1 (en)	2003-10-03	2011-11-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
DE10348044A1 (de)	2003-10-15	2005-05-19	Imtm Gmbh	Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de)	2003-10-15	2005-05-25	Imtm Gmbh	Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en)	2003-10-16	2003-11-19	Astrazeneca Ab	Chemical compounds
TW200519105A (en)	2003-10-20	2005-06-16	Lg Life Science Ltd	Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
PE20050444A1 (es)	2003-10-31	2005-08-09	Takeda Pharmaceutical	Compuestos de piridina como inhibidores de la peptidasa
CN1870990A (zh)	2003-11-04	2006-11-29	默克公司	作为糖尿病治疗或预防用二肽基肽酶iv抑制剂的稠合苯基丙氨酸衍生物
WO2005047297A1 (en)	2003-11-12	2005-05-26	Phenomix Corporation	Heterocyclic boronic acid compounds
KR20150028829A (ko)	2003-11-17	2015-03-16	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
DE10355304A1 (de) *	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005058849A1 (en)	2003-12-15	2005-06-30	Glenmark Pharmaceuticals Ltd.	New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en) *	2003-12-17	2007-05-15	Boehringer Ingelheim International Gmbh	Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (de)	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
AU2004303604B2 (en)	2003-12-24	2011-03-24	Prosidion Limited	Heterocyclic derivatives as GPCR receptor agonists
US20080227786A1 (en)	2004-01-16	2008-09-18	Ferlita Russell R	Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
WO2005075426A1 (en)	2004-02-03	2005-08-18	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
RU2394570C2 (ru)	2004-02-20	2010-07-20	Новартис Аг	Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
BRPI0507972A (pt)	2004-02-23	2007-07-24	Tufts College	composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
CN101090885A (zh)	2004-02-23	2007-12-19	塔夫茨大学信托人	作为构象限定的肽模拟物抑制剂的内酰胺类化合物
CA2559611C (en)	2004-03-09	2012-01-17	National Health Research Institutes	Pyrrolidine compounds
WO2005121121A2 (en) *	2004-06-04	2005-12-22	Arena Pharmaceuticals, Inc.	Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060024313A1 (en) *	2004-07-06	2006-02-02	Xin Chen	Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
WO2006019965A2 (en) *	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE102004037554A1 (de)	2004-08-03	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038268A1 (de)	2004-08-06	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060046978A1 (en) *	2004-08-31	2006-03-02	Morphochem Ag	Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080076805A1 (en) *	2004-10-07	2008-03-27	Lin Linus S	Acyclic Hydrazides as Cannabinoid Receptor Modulators
CN101035522B (zh) *	2004-10-25	2011-12-07	诺瓦提斯公司	Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
US7411093B2 (en) *	2004-12-20	2008-08-12	Hoffman-La Roche Inc.	Aminocycloalkanes as DPP-IV inhibitors
JP2008524331A (ja) *	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
JPWO2006068163A1 (ja)	2004-12-24	2008-06-12	大日本住友製薬株式会社	二環性ピロール誘導体
US7589088B2 (en) *	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20070032420A1 (en) *	2005-02-09	2007-02-08	Entelos, Inc.	Treating diabetes with glucagon-like peptide-1 secretagogues
WO2007027225A2 (en) *	2005-04-27	2007-03-08	Arena Pharmaceuticals, Inc.	Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
CA2611446A1 (en)	2005-06-09	2006-12-14	Banyu Pharmaceutical Co., Ltd.	Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
US20090325924A1 (en) *	2005-06-30	2009-12-31	Stuart Edward	GPCR Agonists
US20090221644A1 (en) *	2005-06-30	2009-09-03	Stuart Edward Bradley	Gpcr Agonists
BRPI0612599A2 (pt) *	2005-06-30	2010-11-23	Prosidion Ltd	composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo
US7708191B2 (en) *	2005-07-28	2010-05-04	Edwin Vega	Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
JP4827483B2 (ja) *	2005-10-04	2011-11-30	キヤノン株式会社	核酸試料処理装置
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PT1971862E (pt) *	2006-04-11	2011-02-14	Arena Pharm Inc	Métodos de utilização do receptor gpr119 para identificar compostos úteis para aumentar a massa óssea num indivíduo
WO2008008895A1 (en) *	2006-07-13	2008-01-17	Smithkline Beecham Corporation	Gpr119 agonists for the treatment of diabetes and related disorders
AU2007291254A1 (en) *	2006-08-30	2008-03-06	Inovacia Ab	Pyrimidine compounds for treating GPR119 related disorders
US8101634B2 (en) *	2006-12-06	2012-01-24	Glaxosmithkline Llc	Bicyclic compounds and use as antidiabetics
WO2008076243A2 (en) *	2006-12-14	2008-06-26	Merck & Co., Inc.	Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
EP2280704B1 (en) *	2008-03-31	2015-05-13	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds and uses thereof
EP2146210A1 (en) *	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009150144A1 (en) *	2008-06-10	2009-12-17	Inovacia Ab	New gpr119modulators
CN102149407A (zh) *	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
US20140193463A1 (en) *	2013-01-04	2014-07-10	China Medical University	Peptide for inhibiting dipeptidyl-peptidase iv

2006
- 2006-01-05 DO DO2006000008A patent/DOP2006000008A/es unknown
- 2006-01-06 GT GT200600004A patent/GT200600004A/es unknown
- 2006-01-06 PE PE2006000045A patent/PE20061116A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2010000178A patent/PE20100398A1/es not_active Application Discontinuation
- 2006-01-09 KR KR1020107023765A patent/KR20100129328A/ko not_active Ceased
- 2006-01-09 KR KR1020107010978A patent/KR101016890B1/ko not_active Expired - Fee Related
- 2006-01-09 CA CA2593427A patent/CA2593427C/en not_active Expired - Fee Related
- 2006-01-09 RS RSP-2009/0354A patent/RS51127B/sr unknown
- 2006-01-09 PT PT06717678T patent/PT1758565E/pt unknown
- 2006-01-09 PL PL06717678T patent/PL1758565T5/pl unknown
- 2006-01-09 EP EP08009893A patent/EP1997484A3/en not_active Withdrawn
- 2006-01-09 ES ES06717678T patent/ES2327268T5/es not_active Expired - Lifetime
- 2006-01-09 DE DE602006006765T patent/DE602006006765D1/de not_active Expired - Lifetime
- 2006-01-09 DK DK06717678.4T patent/DK1758565T4/da active
- 2006-01-09 TW TW095100807A patent/TW200637534A/zh unknown
- 2006-01-09 AT AT07004743T patent/ATE432693T1/de active
- 2006-01-09 AU AU2006205164A patent/AU2006205164B2/en not_active Ceased
- 2006-01-09 EP EP07004743A patent/EP1808168B1/en not_active Revoked
- 2006-01-09 EP EP10010819A patent/EP2322151A3/en not_active Withdrawn
- 2006-01-09 DE DE602006007093T patent/DE602006007093D1/de not_active Expired - Lifetime
- 2006-01-09 US US11/328,405 patent/US20060154866A1/en not_active Abandoned
- 2006-01-09 AT AT06717678T patent/ATE431139T1/de active
- 2006-01-09 SG SG2013026273A patent/SG189762A1/en unknown
- 2006-01-09 SI SI200630362T patent/SI1758565T1/sl unknown
- 2006-01-09 EP EP10010820A patent/EP2322152A1/en not_active Withdrawn
- 2006-01-09 EP EP10010818A patent/EP2322150A3/en not_active Withdrawn
- 2006-01-09 HN HN2006000971A patent/HN2006000971A/es unknown
- 2006-01-09 CA CA2654733A patent/CA2654733C/en not_active Expired - Fee Related
- 2006-01-09 NZ NZ587368A patent/NZ587368A/en not_active IP Right Cessation
- 2006-01-09 EP EP10010659A patent/EP2322157A1/en not_active Withdrawn
- 2006-01-09 NZ NZ556219A patent/NZ556219A/en not_active IP Right Cessation
- 2006-01-09 CN CN2011100978256A patent/CN102218141A/zh active Pending
- 2006-01-09 SG SG201000208-7A patent/SG158876A1/en unknown
- 2006-01-09 KR KR1020127029863A patent/KR20120139849A/ko not_active Withdrawn
- 2006-01-09 MX MX2007008376A patent/MX2007008376A/es active IP Right Grant
- 2006-01-09 WO PCT/US2006/000510 patent/WO2006076231A2/en not_active Ceased
- 2006-01-09 NZ NZ578502A patent/NZ578502A/en not_active IP Right Cessation
- 2006-01-09 AR ARP060100072A patent/AR052082A1/es unknown
- 2006-01-09 PL PL07004743T patent/PL1808168T3/pl unknown
- 2006-01-09 BR BRPI0606727-1A patent/BRPI0606727A/pt not_active IP Right Cessation
- 2006-01-09 DK DK07004743T patent/DK1808168T3/da active
- 2006-01-09 RS RSP-2009/0366A patent/RS51174B/sr unknown
- 2006-01-09 CN CN201310606771.0A patent/CN103611161A/zh active Pending
- 2006-01-09 JP JP2007550512A patent/JP4118323B1/ja not_active Expired - Fee Related
- 2006-01-09 EP EP10010656A patent/EP2322156A1/en not_active Withdrawn
- 2006-01-09 KR KR1020077018318A patent/KR20070095400A/ko not_active Ceased
- 2006-01-09 ES ES07004743T patent/ES2327872T3/es not_active Expired - Lifetime
- 2006-01-09 KR KR1020137032119A patent/KR20130140226A/ko not_active Ceased
- 2006-01-09 EA EA200701469A patent/EA011883B1/ru not_active IP Right Cessation
- 2006-01-09 NZ NZ578504A patent/NZ578504A/en not_active IP Right Cessation
- 2006-01-09 SI SI200630363T patent/SI1808168T1/sl unknown
- 2006-01-09 HR HRP20090403TT patent/HRP20090403T4/hr unknown
- 2006-01-09 PT PT07004743T patent/PT1808168E/pt unknown
- 2006-01-09 EP EP09006268A patent/EP2116235A1/en not_active Withdrawn
- 2006-01-09 EP EP06717678A patent/EP1758565B2/en not_active Expired - Lifetime
- 2006-01-10 PA PA20068659301A patent/PA8659301A1/es unknown
- 2006-11-22 US US11/603,410 patent/US7803753B2/en not_active Expired - Fee Related
- 2006-11-22 US US11/603,417 patent/US7803754B2/en not_active Expired - Fee Related
2007
- 2007-07-02 CR CR9220A patent/CR9220A/es not_active Application Discontinuation
- 2007-07-02 IL IL184364A patent/IL184364A0/en unknown
- 2007-07-09 NI NI200700174A patent/NI200700174A/es unknown
- 2007-07-20 NO NO20073816A patent/NO331089B1/no not_active IP Right Cessation
- 2007-09-06 JP JP2007232094A patent/JP4787804B2/ja not_active Expired - Fee Related
2008
- 2008-03-17 JP JP2008068598A patent/JP4237243B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068596A patent/JP4807887B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068597A patent/JP4221444B2/ja not_active Expired - Fee Related
- 2008-04-16 JP JP2008107320A patent/JP4912349B2/ja not_active Expired - Fee Related
2009
- 2009-07-17 AU AU2009202898A patent/AU2009202898B2/en not_active Ceased
- 2009-07-17 AU AU2009202900A patent/AU2009202900B8/en not_active Ceased
- 2009-08-03 CY CY20091100816T patent/CY1109260T1/el unknown
- 2009-08-19 CY CY20091100881T patent/CY1109321T1/el unknown
- 2009-08-20 HR HR20090446T patent/HRP20090446T1/hr unknown
- 2009-10-30 US US12/609,599 patent/US20100137293A1/en not_active Abandoned
- 2009-11-02 US US12/610,490 patent/US20100285494A1/en not_active Abandoned
- 2009-11-02 US US12/610,918 patent/US20100286153A1/en not_active Abandoned
- 2009-11-02 US US12/610,674 patent/US8030270B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,639 patent/US8198232B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,877 patent/US8022034B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,885 patent/US20100286168A1/en not_active Abandoned
- 2009-11-02 US US12/610,682 patent/US8003597B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,967 patent/US20100298333A1/en not_active Abandoned
2010
- 2010-05-31 CL CL2010000565A patent/CL2010000565A1/es unknown
- 2010-12-09 NO NO20101746A patent/NO20101746L/no not_active Application Discontinuation
2011
- 2011-02-01 DO DO2011000040A patent/DOP2011000040A/es unknown
- 2011-06-07 JP JP2011127707A patent/JP2011184458A/ja not_active Withdrawn
- 2011-08-05 JP JP2011172381A patent/JP2012017330A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP4807887B2 (ja)	2011-11-02
SG158876A1 (en)	2010-02-26
EP2322151A2 (en)	2011-05-18
WO2006076231A3 (en)	2007-01-18
US20070072803A1 (en)	2007-03-29
DK1758565T4 (da)	2013-02-04
CY1109260T1 (el)	2014-07-02
NZ587368A (en)	2011-01-28
US20100286172A1 (en)	2010-11-11
NZ578502A (en)	2011-01-28
US8003597B2 (en)	2011-08-23
EP2322151A3 (en)	2012-01-18
EP2322156A1 (en)	2011-05-18
DK1758565T3 (da)	2009-09-07
NZ556219A (en)	2010-09-30
EP2322150A3 (en)	2011-11-16
WO2006076231A2 (en)	2006-07-20
JP2008110964A (ja)	2008-05-15
ES2327268T3 (es)	2009-10-27
AU2006205164B2 (en)	2011-09-08
CN103611161A (zh)	2014-03-05
EP1808168B1 (en)	2009-06-03
JP2008195733A (ja)	2008-08-28
KR20100129328A (ko)	2010-12-08
AU2009202900A1 (en)	2009-08-06
JP4237243B2 (ja)	2009-03-11
EP1997484A2 (en)	2008-12-03
CR9220A (es)	2009-07-31
EP2322157A1 (en)	2011-05-18
DE602006007093D1 (de)	2009-07-16
NO20101746L (no)	2007-09-27
US20100291589A1 (en)	2010-11-18
GT200600004A (es)	2006-09-11
SI1758565T1 (sl)	2009-10-31
JP4118323B1 (ja)	2008-07-16
AU2006205164A1 (en)	2006-07-20
US8022034B2 (en)	2011-09-20
CA2654733A1 (en)	2006-07-20
KR20120139849A (ko)	2012-12-27
CN102218141A (zh)	2011-10-19
KR20100072085A (ko)	2010-06-29
PT1808168E (pt)	2009-08-25
JP4221444B2 (ja)	2009-02-12
DE602006006765D1 (de)	2009-06-25
EA011883B1 (ru)	2009-06-30
AR052082A1 (es)	2007-02-28
US20100286111A1 (en)	2010-11-11
BRPI0606727A (pt)	2008-03-11
JP4787804B2 (ja)	2011-10-05
EP1997484A3 (en)	2009-02-11
ES2327268T9 (es)	2013-11-12
JP2008220375A (ja)	2008-09-25
JP2008220374A (ja)	2008-09-25
NI200700174A (es)	2008-05-09
CA2593427A1 (en)	2006-07-20
EP1758565B2 (en)	2012-11-14
US7803753B2 (en)	2010-09-28
US20100285494A1 (en)	2010-11-11
CY1109321T1 (el)	2014-07-02
AU2009202900B2 (en)	2010-02-11
JP2008239623A (ja)	2008-10-09
US20100286153A1 (en)	2010-11-11
SI1808168T1 (sl)	2009-10-31
EP1808168A1 (en)	2007-07-18
PE20100398A1 (es)	2010-06-07
IL184364A0 (en)	2007-10-31
AU2009202900B8 (en)	2010-06-03
HRP20090446T1 (hr)	2009-09-30
SG189762A1 (en)	2013-05-31
EP1758565A2 (en)	2007-03-07
ATE432693T1 (de)	2009-06-15
JP2011184458A (ja)	2011-09-22
JP2012017330A (ja)	2012-01-26
CL2010000565A1 (es)	2010-10-15
RS51174B (sr)	2010-10-31
EP2116235A1 (en)	2009-11-11
HN2006000971A (es)	2011-12-27
NO20073816L (no)	2007-09-27
US20100137293A1 (en)	2010-06-03
EP2322150A2 (en)	2011-05-18
PL1808168T3 (pl)	2009-11-30
HK1096537A1 (en)	2007-06-01
RS51127B (sr)	2010-10-31
US20060154866A1 (en)	2006-07-13
ES2327268T5 (es)	2013-03-21
KR20070095400A (ko)	2007-09-28
MX2007008376A (es)	2008-01-11
NZ578504A (en)	2011-02-25
US8030270B2 (en)	2011-10-04
US20100286168A1 (en)	2010-11-11
US7803754B2 (en)	2010-09-28
CA2593427C (en)	2011-11-29
DOP2011000040A (es)	2011-09-30
KR101016890B1 (ko)	2011-02-22
EP2322152A1 (en)	2011-05-18
HRP20090403T4 (hr)	2012-12-31
US20100285495A1 (en)	2010-11-11
HRP20090403T1 (hr)	2009-08-31
PL1758565T3 (pl)	2009-10-30
TW200637534A (en)	2006-11-01
PT1758565E (pt)	2009-08-19
US8198232B2 (en)	2012-06-12
US20100298333A1 (en)	2010-11-25
PA8659301A1 (es)	2008-12-18
ES2327872T3 (es)	2009-11-04
AU2009202898A1 (en)	2009-08-06
EA200701469A1 (ru)	2008-02-28
HK1100353A1 (en)	2007-09-21
EP1758565B1 (en)	2009-05-13
NO331089B1 (no)	2011-10-03
CA2654733C (en)	2011-09-06
AU2009202898B2 (en)	2010-02-18
JP4912349B2 (ja)	2012-04-11
ATE431139T1 (de)	2009-05-15
WO2006076231A8 (en)	2006-09-21
US20070072804A1 (en)	2007-03-29
DOP2006000008A (es)	2006-08-31
KR20130140226A (ko)	2013-12-23
PE20061116A1 (es)	2006-10-12
JP2008526235A (ja)	2008-07-24
PL1758565T5 (pl)	2013-03-29

Publication	Publication Date	Title
DK1808168T3 (da)	2009-10-05	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau
DK1942898T3 (da)	2012-01-09	Dipeptidylpeptidase-inhibitorer til behandling af diabetes
DK2347762T3 (da)	2019-06-11	Exendin til behandling af diabetes og reduktion af kropsvægt
ZA200706294B (en)	2008-09-25	Roflumilast for the treatment of diabetes mellitus
DK1869025T3 (da)	2011-04-04	Piperazin-substituerede benzothiophener til behandling af mentale lidelser
DK2451482T3 (da)	2019-07-22	Kombinationsterapi til behandlingen af diabetes
DK1833532T3 (da)	2011-06-06	Sikkerhedssprøjte
DE502005009922D1 (de)	2010-08-26	Faltbare intravasal einführbare blutpumpe
DK1959981T3 (da)	2020-01-27	Anti-connexin 43 forbindelser til behandling af kroniske sår
DK1853271T3 (da)	2011-01-24	Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1928438T3 (da)	2013-04-22	Anvendelse af ibudilast til behandling af stofafhængighed
DK2240135T3 (da)	2021-11-08	Apparat til behandling af fedme og reflukssygdom
EP1782832A4 (en)	2009-08-26	MEANS FOR THE TREATMENT OF DIABETES
EA201891510A1 (ru)	2018-12-28	Вазопротективное и кардиопротективное противодиабетическое лечение
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1830843T3 (da)	2013-02-11	Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK2533050T3 (da)	2014-06-02	Behandlingsmuligheder ved Fabrys sygdom
DK1865976T3 (da)	2012-07-23	Anvendelse af natriuretiske peptider til behandling af hjertesvigt
DK1928850T3 (da)	2013-09-23	Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
DK3403657T3 (da)	2022-02-28	Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1685834T3 (da)	2009-07-20	Anvendelse af pinolensyre til behandling af obesitet
IL177232A0 (en)	2006-12-10	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP1970063A4 (en)	2014-05-21	THERAPEUTIC AGENT AGAINST DIABETES
DK2172207T3 (da)	2013-04-08	Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
DK2234631T3 (da)	2013-01-07	Forbindelser og fremgangsmåder til behandling af vaskulær sygdom